Outlook Wealth Advisors LLC boosted its position in shares of Zoetis Inc (NYSE:ZTS) by 414.2% during the 1st quarter, according to its most recent 13F filing with the SEC. The fund owned 3,651 shares of the company’s stock after purchasing an additional 2,941 shares during the quarter. Outlook Wealth Advisors LLC’s holdings in Zoetis were worth $368,000 at the end of the most recent reporting period.
Other hedge funds have also recently made changes to their positions in the company. Farmers & Merchants Trust Co of Chambersburg PA purchased a new position in shares of Zoetis in the first quarter worth approximately $25,000. Berman Capital Advisors LLC purchased a new position in shares of Zoetis in the fourth quarter worth approximately $26,000. Athena Capital Advisors LLC purchased a new position in shares of Zoetis in the fourth quarter worth approximately $29,000. Resources Investment Advisors Inc. purchased a new position in shares of Zoetis in the fourth quarter worth approximately $31,000. Finally, Lavaca Capital LLC purchased a new position in shares of Zoetis in the fourth quarter worth approximately $32,000. 90.84% of the stock is currently owned by institutional investors.
A number of equities analysts recently issued reports on the stock. BMO Capital Markets raised their price objective on shares of Zoetis from $101.00 to $105.00 and gave the stock a “market perform” rating in a report on Thursday, May 9th. UBS Group assumed coverage on shares of Zoetis in a report on Wednesday, March 20th. They issued a “neutral” rating on the stock. Stifel Nicolaus upgraded shares of Zoetis from a “hold” rating to a “buy” rating and raised their target price for the stock from $97.00 to $110.00 in a research note on Monday, March 4th. Zacks Investment Research upgraded shares of Zoetis from a “sell” rating to a “hold” rating in a research note on Saturday, February 16th. Finally, SunTrust Banks assumed coverage on shares of Zoetis in a research note on Tuesday, March 19th. They set a “hold” rating and a $100.00 target price on the stock. Six research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company. The company has an average rating of “Buy” and an average price target of $103.15.
Zoetis (NYSE:ZTS) last released its earnings results on Thursday, May 2nd. The company reported $0.88 EPS for the quarter, topping analysts’ consensus estimates of $0.79 by $0.09. Zoetis had a net margin of 23.47% and a return on equity of 73.66%. The company had revenue of $1.46 billion for the quarter, compared to analysts’ expectations of $1.45 billion. During the same quarter last year, the business earned $0.75 EPS. The firm’s revenue was up 6.5% compared to the same quarter last year. As a group, analysts expect that Zoetis Inc will post 3.47 earnings per share for the current year.
The company also recently announced a quarterly dividend, which will be paid on Monday, June 3rd. Shareholders of record on Thursday, April 18th will be paid a dividend of $0.164 per share. This represents a $0.66 dividend on an annualized basis and a yield of 0.65%. The ex-dividend date of this dividend is Wednesday, April 17th. Zoetis’s payout ratio is 21.09%.
In other news, EVP Clinton A. Jr. Lewis sold 6,124 shares of Zoetis stock in a transaction that occurred on Monday, April 15th. The shares were sold at an average price of $101.60, for a total transaction of $622,198.40. Following the sale, the executive vice president now owns 54,484 shares in the company, valued at $5,535,574.40. The transaction was disclosed in a document filed with the SEC, which is available at this link. Also, insider Roxanne Lagano sold 29,453 shares of Zoetis stock in a transaction that occurred on Friday, May 10th. The shares were sold at an average price of $101.65, for a total transaction of $2,993,897.45. Following the sale, the insider now owns 58,180 shares in the company, valued at approximately $5,913,997. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 428,286 shares of company stock worth $40,670,360. 0.29% of the stock is owned by company insiders.
Zoetis Company Profile
Zoetis Inc discovers, develops, manufactures, and commercializes animal health medicines, vaccines, and diagnostic products in the United States and internationally. It commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep; and companion animals comprising dogs, cats, and horses.
Further Reading: How do taxes affect a CDs total return?
Want to see what other hedge funds are holding ZTS? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Zoetis Inc (NYSE:ZTS).
Receive News & Ratings for Zoetis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Zoetis and related companies with MarketBeat.com's FREE daily email newsletter.